SCHEDULE: Lindesfarne LLC Discloses 9.88% Stake in Lakewood-Amedex

Lindesfarne LLC has reported a beneficial ownership of 203,360 shares, representing 9.88% of the common stock of Lakewood-Amedex Biotherapeutics Inc., as of April 17, 2026.

Summary

• Lindesfarne LLC has filed a Schedule 13G, indicating it beneficially owns 203,360 shares of Lakewood-Amedex Biotherapeutics Inc. common stock.
• This ownership stake represents 9.88% of the class of securities.
• The filing date for this event is April 17, 2026.
• Lindesfarne LLC is organized in Nevada and its managing member is Steve Parkinson.
• The filing certifies that the securities were not acquired for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant ownership stake without immediate strategic implications.

Positives

• Significant institutional ownership stake established by Lindesfarne LLC.
• The filing confirms a substantial percentage (9.88%) of the company's common stock is held by a single entity.
• The certification by Lindesfarne LLC suggests a passive investment approach rather than an activist one.

Negatives

• The filing does not provide details on the investment strategy or future intentions of Lindesfarne LLC.
• The exact cost basis or acquisition dates of the shares are not disclosed.

Risks

• Potential for future changes in Lindesfarne LLC's stake, which could impact share price volatility.
• Lack of transparency regarding the specific reasons for acquiring this significant stake.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Lakewood-Amedex Biotherapeutics Inc. It solely reports on the ownership status of Lindesfarne LLC.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with or as a participant in any transaction having that purpose or effect."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders. This filing indicates a notable passive stake in a biotechnology company, a sector often subject to significant investor interest and potential volatility.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership positively, but the passive nature of the filing offers little immediate insight into strategic direction.
• Management: The filing confirms a significant passive investor, which could influence future strategic decisions if the investor's stance evolves.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitor future filings from Lindesfarne LLC for any changes in ownership or investment strategy.
• Observe Lakewood-Amedex Biotherapeutics Inc.'s corporate actions and financial performance for potential impact of this ownership stake.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Lakewood-Amedex Biotherapeutics, Lindesfarne LLC, Common Stock, Institutional Investor, Securities Exchange Act